Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TREAT-PD

Financiado

Cerrado

Patient specific treatment for Parkinson s disease using reprogrammed skin cells

Cellular reprogramming is a new and rapidly emerging field where somatic cells can be turned into pluripotent stem cells or other somatic cell types simply by overexpression of specific combinations of genes. This remarkable disco... ver más

31/10/2023

LUNDS UNIVERSITET

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-10-31

ERC-2017-COG: ERC Consolidator Grant

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

LUNDS UNIVERSITET

2.00M€ | Lider

INFINITEC ACTIVOS

350.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PreciseCellPD A PRECISION CELL REPLACEMENT STRATEGY FOR PARKINSON S DISEA... 3M€ Cerrado

REPROPARK New experimental therapeutic approaches for Parkinson s dise... 2M€ Cerrado

SAF2015-71140-R DESARROLLO, DIFERENCIACION Y MADURACION DE LAS NEURONAS DOPA... 97K€ Cerrado

NEUROSTEMCELLREPAIR European stem cell consortium for neural cell replacement r... 8M€ Cerrado

SPARK Human Stem cell-based technologies to model PARKinson’s dise... 189K€ Cerrado

NEUROSTEMCELL European Consortium for Stem Cell Therapy for Neurodegenerat... 16M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2018-10-11
Fecha Fin: 2023-10-31

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cellular reprogramming is a new and rapidly emerging field where somatic cells can be turned into pluripotent stem cells or other somatic cell types simply by overexpression of specific combinations of genes. This remarkable discovery allows for the generation of patient specific cell lines that will serve as major tools for understanding how diseases arise and develop, and they may also prove useful for drug screens, diagnostics and other biomedical applications. We have developed a reprogramming technique that directly converts human fibroblasts to functional dopamine (DA) neurons, which is the subtype that is affected in Parkinson’s Disease (PD). This opens up for possibilities to generate therapeutic neurons, including patient specific neurons on demand. These neurons, and the techniques for producing them, will become valuable tools for understanding and treating neurodegenerative diseases such as PD. Direct cell conversion is of particular interest for cell replacement therapy as the reprogramming does not involve a proliferating cell intermediate, and thus the risk of uncontrolled proliferation and tumor formation after transplantation is minimized. This project integrates mechanistic studies based on single cell sequencing to improve the technology and control of cell fate such that a large number of authentic DA neurons are obtained. Induced DA neurons will be generated from individuals with PD and age matched healthy donors and subjected to comparative assessments in vitro and in vivo in order to investigate whether any potential PD-associated pathology emerges in the patient derived cells. This will then guide future decisions regarding autologous vs. allogeneic donors. The cells will be extensively validated using pre-clinical animal models of PD. The studies will include direct comparison with primary fetal and hESC-derived DA neurons on criteria important for clinical use such as midbrain subtype identity and in vivo potency and efficacy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores